Get the Stockscreener App
36.01
0.22%
0.08
Ideaya Biosciences Inc stock is traded at $36.01, with a volume of 938.88K.
It is up +0.22% in the last 24 hours and up +15.20% over the past month.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
See More
Previous Close:
$35.93
Open:
$35.19
24h Volume:
938.88K
Relative Volume:
0.78
Market Cap:
$3.47B
Revenue:
$225.27M
Net Income/Loss:
$-140.06M
P/E Ratio:
-22.54
EPS:
-1.5974
Net Cash Flow:
$-87.93M
1W Performance:
-2.65%
1M Performance:
+15.20%
6M Performance:
+0.47%
1Y Performance:
+63.01%
1-Day Range:
$35.11
$36.73
1-Week Range:
$35.11
$37.01
52-Week Range:
$21.33
$40.58
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Name
Ideaya Biosciences Inc
Sector
Industry
Phone
650-443-6209
Address
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
36.01 | 3.46B | 225.27M | -140.06M | -87.93M | -1.5974 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Buy |
| Nov-24-25 | Initiated | Truist | Buy |
| Sep-18-25 | Initiated | Guggenheim | Buy |
| Sep-04-25 | Initiated | Barclays | Overweight |
| Sep-04-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-22-25 | Initiated | TD Cowen | Buy |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Jun-26-25 | Initiated | Wells Fargo | Overweight |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Nov-05-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-15-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Mar-08-24 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | SVB Securities | Outperform |
| May-24-23 | Initiated | Goldman | Buy |
| Apr-24-23 | Upgrade | Stifel | Hold → Buy |
| Mar-23-23 | Initiated | Berenberg | Buy |
| Feb-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Dec-28-22 | Initiated | CapitalOne | Overweight |
| Oct-27-22 | Initiated | Citigroup | Buy |
| Aug-15-22 | Downgrade | Stifel | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-10-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Mar-11-21 | Initiated | Guggenheim | Buy |
| Oct-07-20 | Initiated | Wedbush | Outperform |
| Sep-01-20 | Initiated | Northland Capital | Outperform |
| Jul-13-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-06-20 | Initiated | H.C. Wainwright | Buy |
| Mar-13-20 | Initiated | ROTH Capital | Buy |
| Oct-17-19 | Initiated | Oppenheimer | Outperform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Jun-17-19 | Initiated | Citigroup | Buy |
| Jun-17-19 | Initiated | JP Morgan | Neutral |
| Jun-17-19 | Initiated | Jefferies | Buy |
View All
Ideaya Biosciences Inc Stock (IDYA) Latest News
IDEAYA melanoma data and partner Hengrui's lung cancer results head to ESMO - Stock Titan
Ideaya Biosciences chief accounting officer sells $382,130 in stock - Investing.com
Ideaya Biosciences chief accounting officer sells $382,130 in stock By Investing.com - Investing.com Nigeria
Form 4 Ideaya Biosciences Inc For: 9 July By Investing.com - Investing.com Nigeria
IDEAYA Biosciences (IDYA) CAO exercises options, sells 9,550 pre-planned shares - Stock Titan
Ideaya Biosciences highlights its precision oncology pipeline as Nasdaq-listed cancer drug developer - ad-hoc-news.de
IDEAYA Biosciences (IDYA) 7th Annual Evercore ISI HealthCONx Healthcare Conference summary - Quartr
How Ideaya Biosciences Inc. (IDYA) Affects Rotational Strategy Timing - Stock Traders Daily
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO - AOL.com
Form 144 IDEAYA Biosciences For: 7 July By Investing.com - Investing.com South Africa
[144] IDEAYA Biosciences, Inc. SEC Filing - Stock Titan
Truist Financial Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $63 - Moomoo
RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $48 - Moomoo
IDYA Maintains Outperform Rating by RBC Capital -- Price Target Lowered to $48 - GuruFocus
RBC Capital Adjusts IDEAYA Biosciences Price Target to $48 From $53, Maintains Outperform Rating - Moomoo
Ideaya Biosciences stock hits 52-week high at $39.28 By Investing.com - Investing.com South Africa
Ideaya Biosciences stock hits 52-week high at $39.28 - Investing.com
How Investors Are Reacting To IDEAYA Biosciences (IDYA) Broad Russell Growth Index Inclusion - simplywall.st
IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 2500 Growth Benchmark - marketscreener.com
IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 2000 Growth Benchmark - marketscreener.com
IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 3000E Growth Benchmark - marketscreener.com
Enterprise value to EBIT forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView
Enterprise value to EBITDA forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView
Enterprise value to EBIT forward of IDEAYA Biosciences, Inc. – FWB:30J - TradingView
Enterprise value to revenue forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView
Enterprise value to revenue forward of IDEAYA Biosciences, Inc. – FWB:30J - TradingView
Price to book forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView
Price to book forward of IDEAYA Biosciences, Inc. – FWB:30J - TradingView
IDEAYA Biosciences, Inc.(NasdaqGS: IDYA) added to Russell 3000 Growth Benchmark - marketscreener.com
Price to sales forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView
Price to earnings forward of IDEAYA Biosciences, Inc. – NASDAQ:IDYA - TradingView
Price to sales forward of IDEAYA Biosciences, Inc. – FWB:30J - TradingView
Price to earnings forward of IDEAYA Biosciences, Inc. – FWB:30J - TradingView
IDEAYA Biosciences, Inc. Actuals & Estimates (SWB:30J) - TradingView
30J Forecast — Price Target — Prediction for 2027 - TradingView
(IDYA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
IDEAYA Biosciences, Inc. Actuals & Estimates (DUS:30J) - TradingView
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GuruFocus
IDEAYA Biosciences, Inc. Actuals & Estimates (NASDAQ:IDYA) - TradingView
IDYA Forecast — Price Target — Prediction for 2027 - TradingView
IDEAYA Biosciences Shareholders Back Leadership, Governance Changes - TipRanks
Shareholders back IDEAYA (NASDAQ: IDYA) proposals as board names new chair - Stock Titan
IDEAYA Biosciences Inc (IDYA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Director at IDEAYA Biosciences (IDYA) receives 20,000-share stock option grant - Stock Titan
IDEAYA Biosciences (IDYA) director receives stock options on 20,000 shares - Stock Titan
IDEAYA (IDYA) director receives grant of 20,000 stock options - Stock Titan
IDEAYA (IDYA) director Terry Rosen receives 20,000 stock options at $30.57 - Stock Titan
IDEAYA (IDYA) director Scott Morrison receives grant of 20,000 stock options - Stock Titan
IDEAYA Biosciences (IDYA) director awarded stock options on 20,000 shares - Stock Titan
IDEAYA Biosciences Inc (IDYA) Institutional Confidence - TradingKey
Ideaya Biosciences Inc Stock (IDYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ideaya Biosciences Inc Stock (IDYA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ruiz Briseno Andres | Chief Accounting Officer |
Jul 07 '26 |
Sale |
40.01 |
9,550 |
382,131 |
26,466 |
0.80%
2.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):